Cosmo Pharmaceuticals N.V.
CMOPF
Other OTC92.20
USD
-0.40
- -
ISIN
NL0011832936
Return %
Stock
S&P500
1Y
43.23
26.53
3Y
65.38
76.60
5Y
-5.68
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Giovanni Di Napoli
- Full Time Employees
- 321
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Riverside II Dublin Ireland 2
- IPO Date
- Jul 31, 2017
- Website
- cosmopharma.com
- Similar Companies
- Business
- Cosmo Pharmaceuticals N.V. (CMOPF) develops and commercializes pharmaceutical products focused on gastroenterology, dermatology, and healthtech, utilizing proprietary multi-matrix MMX technology for targeted colon delivery; core products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment for ulcerative colitis treatment, Winlevi for acne, GI Genius for AI-assisted colorectal polyp detection during colonoscopy, Eleview for gastrointestinal endoscopic procedures, Lumeblue (Methylene Blue MMX) for colon lesion identification, Aemcolo/Relafalk (Rifamycin SV MMX) for travelers' diarrhea, and Byfavo for procedural sedation. The company manufactures at its cGMP-approved plant in Italy and licenses products globally to partners including Medtronic, Bausch Health, Ferring, and Sun Pharmaceutical for marketing and distribution. Founded in 1997 by Mauro Severino Ajani and headquartered in Dublin, Ireland, with operations in Europe and the United States, Cosmo targets unmet needs in inflammatory bowel diseases, colon cancer prevention, skin disorders, and endoscopic care. In 2025, Cosmo announced positive Phase III topline results from SCALP 1 and SCALP 2 trials for clascoterone 5% solution (Breezula) in male pattern hair loss, meeting co-primary endpoints for hair count growth and planning FDA/EMA filings post-12-month safety data in spring 2026; it raised full-year EBITDA guidance by €4.5 million to €5.5-7.5 million after strong H1 performance with GI Genius recurring revenues up 128% and Winlevi up 23%, reconfirmed total revenues of €102-107 million, and sold its Digital Trust asset to streamline its strategic portfolio.
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
Cosmo Pharmaceuticals (OTC:CMOPF) Stock Price Up 1.1% – Here’s What Happened
The Hair-Loss Cure That Just Sent This Stock Exploding 24%--Is Big Pharma Paying Attention?